Genentech's cancer restructure was made 'for scientific reasons': exec

The recent decision to merge Genentech’s two cancer departments was made for “scientific reasons,” executives explained to the media this morning.

The Roche unit announced last month that it was merging its cancer immunology research function with molecular oncology research to form one single cancer research body within Genentech Research and Early Development (gRED).